Immunotherapy Coverage from Every Angle
Advertisement
Advertisement

Ongoing CE Activities

NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
Biomarker Testing in Non–Small Cell Lung Cancer
Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care - Lung Cancer
Consensus or Controversy? Radiation and Medical Oncology Investigator Perspectives on the Role of Immune Checkpoint Inhibition in the Management of Locally Advanced Non–Small Cell Lung Cancer
The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?
The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?
The Nurse View: What Do You Need to Know About Immune Checkpoint Inhibitors?
NCCN Pharmacy Updates: Advances in Targeted Therapy and Immunotherapy for the Treatment of Kidney Cancer
Exploring the Evolving Role of PARP Inhibition and Immunotherapy in Gynecological Cancers
Changing Treatment Landscape of Metastatic Head and Neck Squamous Cell Carcinoma With Anti–PD-1/PD-L1 Agents
Combined CAR-T Targeting Yields High Response Rate in Myeloma
Tumor Mutational Burden, Neoantigens, and a Pathway to Predicting Response to Checkpoint Inhibitors
Immunotherapy for cSCC: How, Why, and When (login required)
Cases From the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients With Genitourinary Cancers
The Emerging Role of Immunotherapy in Head and Neck Cancers: An Integrated Approach (login required)
JADPRO Regional Lectures: Immunotherapy: Head & Neck Case Studies
Expanding Treatment Options in SCCHN: What Role Do Cancer Immunotherapies Have? (login required)
JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity
Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?
Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy
Management of Advanced NSCLC: Where Do Immune Checkpoint Inhibitors Fit In?:
JADPRO Regional Lectures: Immunotherapy: Case Studies in Non-Small Cell Lung Cancer
Integration of Immunotherapies Into the Treatment of Patients With Non–Small Cell Lung Cancer
Immunotherapy in Advanced NSCLC: Will Combination Therapies Become Standard?
NCCN Pharmacy Updates: The Evolving Landscape of Immunotherapy and Targeted Therapy for Non–Small Cell Lung Cancer
Checkpoint Inhibitors in First-Line Advanced NSCLC: What Should You Know?
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care-Lung Cancer: Advanced Disease
Cases from the Community: Clinical Investigators Provide Their Perspectives on the Use of Immune Checkpoint Inhibitors in the Management of Actual Patients with Genitourinary Cancers
JADPRO Regional Lectures: Immunotherapy: Renal Cell & Urothelial
Expert Guidance for Optimizing Immune Checkpoint Inhibitor Therapy for Kidney and Bladder Cancer
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition (login required)
Advanced Renal Cell Carcinoma: combination, sequential strategies, & immunotherapy
JADPRO Regional Lectures: Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond
High-Rick Relapsing MM: Retreatment With Immunomodulatory Therapy
Copyright © 2020 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.